Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

By Z. Dong, W. Zhong, Xuchao Zhang, J. Su, Zhi Xie, S. Liu, H. Tu, Hua-jun Chen, Yue-Li Sun, Qing Zhou and 9 more. Clinical Cancer Research, 2016

830 citations recorded by the source corpus.

Purpose: Although clinical studies have shown promise for targeting programmed cell death protein-1 (PD-1) and ligand (PD-L1) signaling in non–small cell lung cancer (NSCLC), the factors that predict which subtype patients will be responsive to checkpoint blockade are not fully understood. Experimental Design: We performed an integrated analysis on the multiple-dimensional data types including genomic, transcriptomic, proteomic, and clinical data from cohorts of lung adenocarcinoma public (discovery set) and internal (validation set) database and immunotherapeutic patients. Gene set enrichment analysis (GSEA) was used to determine potentially relevant gene expression signatures between specific subgroups. Results: We observed that TP53 mutation significantly increased expression of immune checkpoints and activated T-effector and interferon-γ signature. More importantly, the TP53/KRAS comutated subgroup manifested exclusive increased expression of PD-L1 and a highest proportion of PD-L1+/CD8A+. Meanwhile, TP53- or KRAS-mutated tumors showed prominently increased mutation burden and specifically enriched in the transversion-high (TH) cohort. Further analysis focused on the potential molecular mechanism revealed that TP53 or KRAS mutation altered a group of genes involved in cell-cycle regulating, DNA replication and damage repair. Finally, immunotherapeutic analysis from public clinical trial and prospective observation in our center were further confirmed that TP53 or KRAS mutation patients, especially those with co-occurring TP53/KRAS mutations, showed remarkable clinical benefit to PD-1 inhibitors. Conclusions: This work provides evidence that TP53 and KRAS mutation in lung adenocarcinoma may be served as a pair of potential predictive factors in guiding anti–PD-1/PD-L1 immunotherapy. Clin Cancer Res; 23(12); 3012–24. ©2016 AACR.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/2a6c7b45d1c027daa0c01c313149b98a87eadcfd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Targeting p53 pathways: mechanisms, structures and advances in therapy (2023, background): “TP53 mutations are associated with increased expression of PD-L1, which may be a predictor of response to PD-L1 targeted checkpoint inhibitors.(142) Mutant TP53 contributes to the regulation of tumor cells into an immune microenvironment that is conducive to growth.”
Genomic features of response to combination immunotherapy in patients with advanced non-small cell lung cancer (2018, background): “The association betweenTP53alterations andTMBwasalso seen in a recent report of TCGA lung adenocarcinomadata (Dong et al., 2017), and is perhaps expected given the function of TP53 (Levine and Oren, 2009) and its known association with smoking (Pfeifer et al.”